Werewolf Therapeutics Stock Current Asset
| HOWL Stock | USD 1.33 0.02 1.48% |
Fundamental analysis of Werewolf Therapeutics allows traders to better anticipate movements in Werewolf Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Non Current Assets Total is expected to rise to about 17.5 M this year. Other Current Assets is expected to rise to about 3 M this year. Werewolf | Current Asset | Build AI portfolio with Werewolf Stock |
Werewolf Therapeutics Company Current Asset Analysis
Werewolf Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Werewolf Current Asset Historical Pattern
Today, most investors in Werewolf Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Werewolf Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Werewolf Therapeutics current asset as a starting point in their analysis.
Werewolf Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Werewolf Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Werewolf Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Investing Opportunities Now
Investing OpportunitiesBuild portfolios using our predefined set of ideas and optimize them against your investing preferences |
| All Next | Launch Module |
Werewolf Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (65.11) % | ||||
| Current Valuation | 5.55 M | ||||
| Shares Outstanding | 44.87 M | ||||
| Shares Owned By Insiders | 6.07 % | ||||
| Shares Owned By Institutions | 57.20 % | ||||
| Number Of Shares Shorted | 820.47 K | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.06 X | ||||
| Price To Sales | 53.00 X | ||||
| Revenue | 1.89 M | ||||
| Gross Profit | (52.24 M) | ||||
| EBITDA | (64.05 M) | ||||
| Net Income | (70.52 M) | ||||
| Cash And Equivalents | 145.71 M | ||||
| Cash Per Share | 4.93 X | ||||
| Total Debt | 37.09 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.08 X | ||||
| Book Value Per Share | 1.28 X | ||||
| Cash Flow From Operations | (56.19 M) | ||||
| Short Ratio | 2.38 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 8.33 | ||||
| Number Of Employees | 46 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 60.58 M | ||||
| Total Asset | 126.93 M | ||||
| Retained Earnings | (414.59 M) | ||||
| Working Capital | 97.89 M | ||||
| Net Asset | 126.93 M |
About Werewolf Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Werewolf Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Werewolf Therapeutics Piotroski F Score and Werewolf Therapeutics Altman Z Score analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.